CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The trial involved 317 patients with CLL or SLL, including 247 who previously received BTK inhibitor treatment.
The recently concluded phase 1-2 trial of pirtobrutinib, a highly selective, noncovalent BTK inhibitor, offers promising new hope for patients with relapsed or refractory B-cell cancers such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) previously treated with covalent BTK inhibitors.
Key Points:
- Median number of prior therapy lines for these 247 patients was three.
- Overall response rate to pirtobrutinib was 73.3% and increased to 82.2% when including partial responses with lymphocytosis.
- Median progression-free survival was 19.6 months.
Additional Points:
- Among the 247 patients, 40.5% had received a BCL2 inhibitor such as venetoclax.
- The most common adverse events among all patients were infections (71.0%), bleeding (42.6%), and neutropenia (32.5%).
- Adverse events typical of BTK inhibitors, including hypertension, atrial fibrillation, and major hemorrhage, were infrequent, and only 2.8% of patients discontinued pirtobrutinib due to treatment-related adverse events.
Conclusion:
- Pirtobrutinib demonstrated efficacy in heavily pretreated CLL or SLL patients who had received a covalent BTK inhibitor, with a manageable side-effect profile.
Hematology/Oncology Latest Posts
- 18 Foods to Avoid to Reduce Cancer Risk
- Is Luspatercept the New Standard of Care in Transfusion-Dependent Low-Risk Myelodysplastic Syndromes?
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
- Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy
Did You Know?
As of 2021, chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults, accounting for about one-third of all leukemia cases in the United States.
